AnaptysBio (NASDAQ:ANAB) Director Ecor1 Capital, Llc Acquires 84,120 Shares of Stock

AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) Director Ecor1 Capital, Llc bought 84,120 shares of AnaptysBio stock in a transaction that occurred on Monday, November 16th. The shares were acquired at an average price of $45.66 per share, with a total value of $3,840,919.20. Following the completion of the transaction, the director owned 7,964,214 shares of the company’s stock, valued at $363,646,011.24. This represents a 1.07% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Ecor1 Capital, Llc also recently made the following trade(s):

  • On Wednesday, November 18th, Ecor1 Capital, Llc bought 138,093 shares of AnaptysBio stock. The stock was acquired at an average price of $46.54 per share, for a total transaction of $6,426,848.22.
  • On Tuesday, November 17th, Ecor1 Capital, Llc purchased 152,367 shares of AnaptysBio stock. The stock was acquired at an average cost of $45.66 per share, for a total transaction of $6,957,077.22.

AnaptysBio Stock Performance

Shares of ANAB opened at $47.06 on Thursday. The company has a current ratio of 8.40, a quick ratio of 8.40 and a debt-to-equity ratio of 0.17. The stock has a 50-day moving average price of $49.17 and a 200-day moving average price of $56.27. AnaptysBio, Inc. has a 12-month low of $22.07 and a 12-month high of $72.36.

AnaptysBio (NASDAQ:ANAB – Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The biotechnology company reported $0.11 EPS for the quarter, topping the consensus estimate of ($1.84) by $1.95. The company had revenue of $30.27 million during the quarter, compared to analyst estimates of $25.56 million. AnaptysBio had a negative return on equity of 17.54% and a net margin of 96.30%. Equities analysts expect that AnaptysBio, Inc. will post -1.30 earnings per share for the current year.

Analysts Set New Price Targets

ANAB has been the subject of several research analyst reports. TD Cowen dropped their target price on shares of AnaptysBio from $75.00 to $70.00 and set a “buy” rating for the company in a research report on Tuesday, August 25th. Scotiabank lowered shares of AnaptysBio to a “hold” rating and set a $70.00 price target on the stock. in a report on Tuesday, August 25th. Weiss Ratings reissued a “sell (e+)” rating on shares of AnaptysBio in a report on Wednesday, November 4th. Leerink Partners lowered their price objective on shares of AnaptysBio from $90.00 to $81.00 and set an “outperform” rating on the stock in a research report on Wednesday, September 23rd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of AnaptysBio in a report on Tuesday, September 22nd. Twelve equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $75.67.

View Our Latest Stock Analysis on AnaptysBio

AnaptysBio News Summary

Here’s some of the latest news about ANAB:

  • Positive Sentiment: Director Ecor1 Capital bought a combined 374,580 shares over November 16–18, investing approximately $17.2 million at prices of $45.66–$46.54 per share. The repeated purchases and increased stake may signal confidence in AnaptysBio. SEC insider transaction filing
  • Positive Sentiment: HC Wainwright maintained a Buy rating and a $95 price target, and estimated Q2 2027 EPS of $0.38. The target offers a bullish counterpoint to the company’s current-year consensus estimate of a loss per share. Analyst coverage
  • Neutral Sentiment: AnaptysBio presented at the UBS Global Biopharma Conference, with transcripts published. The available article details do not specify new guidance or developments that would clearly affect the stock. Conference transcript

Hedge Funds Weigh In On AnaptysBio

Hedge funds and other institutional investors have recently modified their holdings of the company. Tema ETFs LLC raised its holdings in shares of AnaptysBio by 0.6% during the 2nd quarter. Tema ETFs LLC now owns 31,270 shares of the biotechnology company’s stock valued at $2,111,000 after buying an additional 201 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al lifted its position in AnaptysBio by 2.3% in the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 17,650 shares of the biotechnology company’s stock worth $887,000 after buying an additional 400 shares during the last quarter. Arizona State Retirement System lifted its position in AnaptysBio by 13.5% in the 2nd quarter. Arizona State Retirement System now owns 4,363 shares of the biotechnology company’s stock worth $295,000 after buying an additional 518 shares during the last quarter. Persistent Asset Partners Ltd bought a new stake in AnaptysBio in the 2nd quarter worth approximately $39,000. Finally, Sterling Capital Management LLC boosted its stake in AnaptysBio by 847.8% in the third quarter. Sterling Capital Management LLC now owns 654 shares of the biotechnology company’s stock worth $33,000 after buying an additional 585 shares in the last quarter.

AnaptysBio Company Profile

(Get Free Report)

AnaptysBio is a biotechnology company focused on developing antibody-based treatments for inflammatory and autoimmune diseases. Its research programs target immune pathways that may be involved in conditions with significant unmet medical needs. The company’s pipeline has included rosnilimab, an investigational antibody designed to activate the PD-1 pathway, and ANB032, an investigational antibody targeting BTLA. AnaptysBio has also developed imsidolimab, an antibody targeting the IL-36 receptor; global rights to that program were licensed to Vanda Pharmaceuticals.

See Also

Insider Buying and Selling by Quarter for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.